|
Video: What is a Stock Split?
|
|
Immutep is a development stage biotech company. Co. is engaged in the development of lymphocyte activation gene 3, or LAG-3, a gene linked to the regulation of T cells in immune responses. Co. focuses on the development of immunotherapeutic products for the treatment of cancer and autoimmune diseases. Co.'s product candidates under development includes: IMP321, a recombinant protein in clinical trials for the treatment of different types of cancers; IMP761, an agonist antibody of LAG-3; IMP701, an antagonist (blocking) antibody targeting the LAG-3 molecule with potential application in the treatment of cancer; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. According to our Immutep stock split history records, Immutep has had 0 splits. | |
|
Immutep (IMMP) has 0 splits in our Immutep stock split history database.
Looking at the Immutep stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Immutep shares, starting with a $10,000 purchase of IMMP, presented on a split-history-adjusted basis factoring in the complete Immutep stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/28/2014 |
|
End date: |
04/24/2024 |
|
Start price/share: |
$1.01 |
|
End price/share: |
$2.59 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
156.44% |
|
Average Annual Total Return: |
9.88% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$25,649.23 |
|
Years: |
10.00 |
|
|
|
|
|